Breakout Setups
RPRX appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
ROYALTY PHARMA PLC- CL A (RPRX) Stock Price & Overview
NASDAQ:RPRX • GB00BMVP7Y09
Current stock price
49.72 USD
+0.24 (+0.49%)
At close:
49.72 USD
0 (0%)
After Hours:
The current stock price of RPRX is 49.72 USD. Today RPRX is up by 0.49%. In the past month the price increased by 9.11%. In the past year, price increased by 54.41%.
RPRX Key Statistics
52-Week Range31.97 - 50.075
Current RPRX stock price positioned within its 52-week range.
1-Month Range45.79 - 50.075
Current RPRX stock price positioned within its 1-month range.
- Market Cap
- 28.685B
- P/E
- 11.22
- Fwd P/E
- 9.62
- EPS (TTM)
- 4.43
- Dividend Yield
- 1.94%
RPRX Stock Performance
Today
+0.49%
1 Week
+2.09%
1 Month
+9.11%
3 Months
+23.07%
Longer-term
6 Months +33.44%
1 Year +54.41%
2 Years +79.49%
3 Years +41.45%
5 Years +13.00%
10 Years N/A
RPRX Stock Chart
RPRX Stock Screens
RPRX currently appears in the following ChartMill screener lists.
RPRX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RPRX. When comparing the yearly performance of all stocks, RPRX is one of the better performing stocks in the market, outperforming 86.59% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
RPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RPRX. RPRX has an excellent profitability rating, but there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RPRX Earnings
On February 11, 2026 RPRX reported an EPS of 1.47 and a revenue of 621.99M. The company beat EPS expectations (8.69% surprise) and missed revenue expectations (-23.38% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 11, 2026
PeriodQ4 / 2025
EPS Reported$1.47
Revenue Reported621.99M
EPS Surprise 8.69%
Revenue Surprise -23.38%
RPRX Forecast & Estimates
16 analysts have analysed RPRX and the average price target is 53.03 USD. This implies a price increase of 6.65% is expected in the next year compared to the current price of 49.72.
For the next year, analysts expect an EPS growth of 16.65% and a revenue growth 4.3% for RPRX
Analysts
Analysts83.75
Price Target53.03 (6.66%)
EPS Next Y16.65%
Revenue Next Year4.3%
RPRX Groups
Sector & Classification
RPRX Financial Highlights
Over the last trailing twelve months RPRX reported a non-GAAP Earnings per Share(EPS) of 4.43. The EPS increased by 8.05% compared to the year before.
Income Statements
Revenue(TTM)2.38B
Net Income(TTM)770.95M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.42% | ||
| ROA | 3.93% | ||
| ROE | 11.9% | ||
| Debt/Equity | 1.32 |
Chartmill High Growth Momentum
EPS Q2Q%27.83%
Sales Q2Q%4.71%
EPS 1Y (TTM)8.05%
Revenue 1Y (TTM)5.06%
RPRX Ownership
Ownership
Inst Owners87.73%
Shares576.94M
Float412.69M
Ins Owners1.59%
Short Float %2.91%
Short Ratio3.3
RPRX Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.35 | 853.191B | ||
| JNJ | JOHNSON & JOHNSON | 17.82 | 544.731B | ||
| MRK | MERCK & CO. INC. | 22.17 | 278.01B | ||
| PFE | PFIZER INC | 8.97 | 155.349B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.29 | 121.259B | ||
| ZTS | ZOETIS INC | 16.62 | 49.697B | ||
| VTRS | VIATRIS INC | 5.82 | 17.152B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.35 | 11.291B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.359B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.199B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.101B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.82 | 4.797B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RPRX
Company Profile
Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 100 full-time employees. The company went IPO on 2020-06-16. The company collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Company Info
IPO: 2020-06-16
ROYALTY PHARMA PLC- CL A
110 East 59th Street
New York City NEW YORK 10022 US
CEO: Pablo Legorreta
Employees: 100
Phone: 12128830200
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you describe the business of ROYALTY PHARMA PLC- CL A?
Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 100 full-time employees. The company went IPO on 2020-06-16. The company collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
What is the current price of RPRX stock?
The current stock price of RPRX is 49.72 USD. The price increased by 0.49% in the last trading session.
Does RPRX stock pay dividends?
ROYALTY PHARMA PLC- CL A (RPRX) has a dividend yield of 1.94%. The yearly dividend amount is currently 0.65.
How is the ChartMill rating for ROYALTY PHARMA PLC- CL A?
RPRX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is RPRX stock listed?
RPRX stock is listed on the Nasdaq exchange.
How is the valuation of ROYALTY PHARMA PLC- CL A (RPRX) based on its PE ratio?
The PE ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 11.22. This is based on the reported non-GAAP earnings per share of 4.43 and the current share price of 49.72 USD.
Can you provide the upcoming earnings date for ROYALTY PHARMA PLC- CL A?
ROYALTY PHARMA PLC- CL A (RPRX) will report earnings on 2026-05-06.